James Arnold
Chief Scientific Officer Korecyte Bio
Co-founder & CSO. James has over 20 years of research experience in the field of Immunology. He acquired his DPhil at the University of Oxford and conducted his Postdoctoral research at the University of Cambridge. James established the Tumour Immunology Group at King’s College London in 2012 and has dedicated his team there to developing new immunotherapy strategies for treating cancer. James has sat on Grant Committees for major UK cancer charities and is a Professor in Tumour Immunology and Immunotherapy at King’s College London. James is a co-inventor of HypoxiCAR Immunotherapy.
Seminars
Tuesday 9th February 2027
Selectively & Safely Overcoming the Tumour Microenvironment to Reduce Barriers to Solid Tumour CAR-T Success
1:45 pm
- Understanding solid tumour complexity and their microenvironment to enhance targeting and therapeutic outcomes
- Generating tumour-targeting immune cells tackling heterogeneity and immune suppression to overcome solid tumour defences
- Highlighting the precision and efficacy of HypoxiCAR in delivering highly potent payloads for neuroblastoma elimination
